Combination strategies using OX40 agonists with TLR9 stimulation have resulted in enhanced CD4+ and CD8+ T-cell activity, suppression of regulatory T cells and myeloid-derived suppressor cells, and durable immune memory in HCC models [132]. The gene discussed is CD8A; the disease is hepatocellular carcinoma.